Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years.
- Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years.
- This news follows the recent launch of the Omnipod 5 Automated Insulin Delivery System connected to Dexcom G6 in the UK and Germany.
- “Championing access to real-time CGM technology for people with all types of diabetes is central to our mission at Dexcom,” said Alex Moussa, senior vice president and general manager of EMEA & LATAM at Dexcom.
- “With Dexcom G7, Dexcom G6 and Dexcom ONE, we have the most complete portfolio of CGM systems for people with all types of diabetes and we continue to work on expanding access to our life-changing technology.